| Ytd | 3.21% | |
| 1y | 25.00% |
| Open | 4.67 | Prev Close | 4.50 | Low | 4.50 | High | 4.50 | Mkt Cap | 172.37M |
| Vol | 88.00 | Avg Vol | 4.58K | EPS | -1.73 | P/E | N/A | Forward P/E | -2.96 |
| Beta | 1.08 | Short Ratio | 4.49 | Inst. Own | 5.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-25 | 50-d Avg | 4.08 | 200-d Avg | 4.24 | 1yr Est | 10.37 |
MOLN News
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the ana
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving preci
Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosi
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712Dosing ongoing
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.45) per share which missed the ana
MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast a
HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a B
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MS
Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes
HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a B
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.41) per share which missed the ana
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical deve
HC Wainwright & Co. analyst Robert Burns initiates coverage on Molecular Partners (NASDAQ:MOL
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, ini
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lo
Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccel
Case study with first patient images of half-life engineered MP0712 from compassionate care use show
Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate t
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(1.65) per share which missed the ana
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lo
In H1 2025, Molecular Partners undertook a strategic review of its operations and headcount, with th
MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovari
Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-de